Timothy D Warner

List of Publications by Year
in descending order

256 papers	16,958 citations	22153 59 h-index	16183 124 g-index
268 all docs	268 docs citations	268 times ranked	14549 citing authors

#	Article	IF	Citations
1	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 49-62.	2.4	31
2	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. Pathology, 2022, 54, 746-754.	0.6	2
3	Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet function. Haematologica, 2021, 106, 1423-1432.	3.5	7
4	Cyclooxygenases and the cardiovascular system. , 2021, 217, 107624.		35
5	Proteome and functional decline as platelets age in the circulation. Journal of Thrombosis and Haemostasis, 2021, 19, 3095-3112.	3.8	23
6	Platelet inhibition by P2Y₁₂ antagonists is potentiated by adenosine signalling activators. British Journal of Pharmacology, 2021, 178, 4758-4771.	5.4	7
7	A novel genetic variant in <scp>PTGS1</scp> affects Nâ€glycosylation of cyclooxygenaseâ€1 causing a dominantâ€negative effect on platelet function and bleeding diathesis. American Journal of Hematology, 2021, 96, E83-E88.	4.1	2
8	Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis, 2020, 120, 253-261.	3.4	12
9	Profiling the eicosanoid networks that underlie the antiâ€and proâ€thrombotic effects of aspirin. FASEB Journal, 2020, 34, 10027-10040.	0.5	10
10	Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age. Circulation Research, 2020, 127, 394-396.	4.5	3
11	Loss of GPVI and GPIbÎ± contributes to trauma-induced platelet dysfunction in severely injured patients. Blood Advances, 2020, 4, 2623-2630.	5.2	29
12	Combination of cyclic nucleotide modulators with P2Y 12 receptor antagonists as antiâ€platelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 1705-1713.	3.8	3
13	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
14	Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17444-17449.	7.1	73
15	Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox. Circulation Research, 2019, 125, 847-854.	4.5	22
16	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). British Journal of Pharmacology, 2019, 176, 988-999.	5.4	49
17	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. Journal of Clinical Investigation, 2019, 129, 1845-1862.	8.2	136
18	Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A ₂ Proves Renal Origins of Urinary PGI-M and TX-M. Circulation Research, 2018, 122, 555-559.	4.5	28

#	Article	IF	Citations
19	Platelet responses to pharmacological and physiological interventions in middleâ€aged men with different habitual physical activity levels. Acta Physiologica, 2018, 223, e13028.	3.8	18
20	Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. Platelets, 2018, 29, 686-689.	2.3	16
21	96-well plate-based aggregometry. Platelets, 2018, 29, 650-655.	2.3	27
22	Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. Platelets, 2018, 29, 162-170.	2.3	6
23	In celebration of Professor Gus Bornâ€™s life, 29 July 1921 â€“ 16 April 2018. Platelets, 2018, 29, 743-743.	2.3	0
24	Letter by Mitchell et al Regarding Article, â€œUrinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgmentâ€. Circulation Research, 2018, 122, e84-e85.	4.5	3
25	Inhibition of profibrotic microRNA-21 affects platelets and their releasate. JCI Insight, 2018, 3, .	5.0	30
26	Understanding the cardiovascular effects of low dose aspirin by using a platelet COX-1-/- mouse model. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-2-57.	0.0	0
27	Platelet reactivity in an elderly and healthy population. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR25-2.	0.0	0
28	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 949-956.	2.4	59
29	Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. Biochemical and Biophysical Research Communications, 2017, 484, 762-766.	2.1	10
30	Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1482-1493.	2.4	17
31	Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. Canadian Journal of Physiology and Pharmacology, 2017, 95, 954-960.	1.4	1
32	Human Platelets Utilize Cycloxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. Journal of Biological Chemistry, 2016, 291, 13448-13464.	3.4	15
33	Aspirin inhibits the production of proangiogenic 15(S)â€HETE by platelet cyclooxygenaseâ€1. FASEB Journal, 2016, 30, 4256-4266.	0.5	44
34	Association of MicroRNAs and YRNAs With Platelet Function. Circulation Research, 2016, 118, 420-432.	4.5	167
35	P2Y₁₂ receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British Journal of Clinical Pharmacology, 2016, 81, 621-633.	2.4	27
36	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. Expert Review of Hematology, 2016, 9, 223-225.	2.2	6

#	Article	IF	Citations
37	Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood, 2015, 126, e11-e18.	1.4	28
38	Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovascular Disease, 2015, 4, 204800401561025.	0.7	2
39	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. Vascular Pharmacology, 2015, 71, 70-78.	2.1	37
40	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2122-2133.	2.4	16
41	Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. BMJ Open, 2015, 5, e005750-e005750.	1.9	1
42	Reply to Letter Regarding Article, â€œEvidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugsâ€• Circulation, 2015, 132, e213-4.	1.6	2
43	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregationin vitro: Insights using short thromboelastography. Platelets, 2015, 26, 689-692.	2.3	10
44	Inherited human group IVA cytosolic phospholipase A₂deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. FASEB Journal, 2015, 29, 4568-4578.	0.5	26
45	Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine. Circulation, 2015, 131, 633-642.	1.6	73
46	COX-2 Protects against Atherosclerosis Independently of Local Vascular Prostacyclin: Identification of COX-2 Associated Pathways Implicate Rgl1 and Lymphocyte Networks. PLoS ONE, 2014, 9, e98165.	2.5	56
47	Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-Î±. Gut, 2014, 63, 96-104.	12.1	62
48	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood, 2014, 123, e11-e22.	1.4	60
49	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15812-15817.	7.1	52
50	High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thrombosis Research, 2013, 131, 313-319.	1.7	13
51	Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. Biochemical and Biophysical Research Communications, 2013, 438, 249-256.	2.1	43
52	Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circulation Research, 2013, 112, 595-600.	4.5	366
53	265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION:. Heart, 2013, 99, A139.3-A140.	2.9	1
54	Blockade of the purinergic P2Y ₁₂ receptor greatly increases the platelet inhibitory actions of nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15782-15787.	7.1	52

#	Article	IF	Citations
55	Aspirinâ€triggered 15â€epiâ€lipoxin A₄predicts cyclooxygenaseâ€2 in the lungs of LPSâ€treated mice but not in the circulation: implications for a clinical test. FASEB Journal, 2013, 27, 3938-3946.	0.5	20
56	Reply to Ricciotti et al.: Evidence for vascular COX isoforms. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E184-E184.	7.1	4
57	207 PLATELET COX-1 SUPPORTS THE PRODUCTION OF BOTH PROSTANOIDS AND HETES. Heart, 2013, 99, A114.1-A114.	2.9	0
58	236 DURING ANTI-PLATELET THERAPY PLATELET TURNOVER MAY LEAD TO THE EMERGENCE OF A MINORITY OF UNINHIBITED PLATELETS SUFFICIENT TO INITIATE AND DRIVE PLATELET AGGREGATE FORMATION. Heart, 2013, 99, A126.2-A127.	2.9	0
59	261 P2Y12 INHIBITION GREATLY POTENTIATES THE ANTI-PLATELET EFFECTS OF PROSTACYCLIN AND NITRIC OXIDE. Heart, 2013, 99, A137.2-A138.	2.9	1
60	LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 Expression. PLoS ONE, 2013, 8, e69524.	2.5	54
61	Cox2 reporter gene expression and prostacylin mass spectrometry confirm vascular COXâ€1 dominance for prostacyclin production. FASEB Journal, 2013, 27, lb507.	0.5	0
62	Short thromboelastography and the identification of high platelet reactivity while on and off therapy. Heart, 2012, 98, 679-680.	2.9	1
63	Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. Platelets, 2012, 23, 404-408.	2.3	31
64	Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17597-17602.	7.1	105
65	Smoking, atherothrombosis and clopidogrel. Heart, 2012, 98, 963-964.	2.9	4
66	Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovascular Research, 2012, 93, 674-681.	3.8	48
67	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81â€‰mg With or Without Esomeprazole 20â€‰mg in Healthy Volunteers. American Journal of Cardiovascular Drugs, 2012, 12, 217-224.	2.2	11
68	Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets, 2011, 22, 485-494.	2.3	47
69	Clopidogrel withdrawal: Is there a â€œreboundâ€•phenomenon?. Thrombosis and Haemostasis, 2011, 105, 211-220.	3.4	55
70	Thrombosis Is Reduced by Inhibition of COX-1, but Unaffected by Inhibition of COX-2, in an Acute Model of Platelet Activation in the Mouse. PLoS ONE, 2011, 6, e20062.	2.5	36
71	Antiâ€platelet therapy: cycloâ€oxygenase inhibition and the use of aspirin with particular regard to dual antiâ€platelet therapy. British Journal of Clinical Pharmacology, 2011, 72, 619-633.	2.4	172
72	In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis, 2011, 9, 552-561.	3.8	157

#	Article	IF	Citations
73	Aspirin has little additional antiâ€platelet effect in healthy volunteers receiving prasugrel. Journal of Thrombosis and Haemostasis, 2011, 9, 2050-2056.	3.8	32
74	Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis, 2011, 9, 2103-2105.	3.8	66
75	4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 2011, 30, 106-116.	5.9	47
76	Gasotransmitters and platelets. , 2011, 132, 196-203.		25
77	46 Urinary prostanoid metabolites in healthy volunteers taking prasugrel and aspirin. Heart, 2011, 97, e7-e7.	2.9	0
78	12 Relationship between proportions of P2Y12 inhibited platelets and aggregation in vitro. Heart, 2011, 97, e7-e7.	2.9	0
79	Role of Shear Stress in Endothelial Cell Morphology and Expression of Cyclooxygenase Isoforms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 384-391.	2.4	71
80	Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart, 2011, 97, 1661-1667.	2.9	33
81	30 Investigation of the action of prostaglandin E2 on human platelets. Heart, 2011, 97, e7-e7.	2.9	0
82	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. PLoS ONE, 2011, 6, e26591.	2.5	71
83	22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel. Heart, 2011, 97, e7-e7.	2.9	0
84	Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. Journal of Thrombosis and Haemostasis, 2010, 8, 613-615.	3.8	73
85	Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Tollâ€like receptor 4 responses in macrophages. British Journal of Pharmacology, 2010, 160, 1997-2007.	5.4	22
86	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. Heart, 2010, 96, 1693-1694.	2.9	41
87	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20483-20488.	7.1	55
88	Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thrombosis and Haemostasis, 2009, 102, 772-778.	3.4	43
89	The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARÎ± In Vitro and In Vivo. PLoS ONE, 2009, 4, e7421.	2.5	58
90	Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 706-711.	2.4	113

#	Article	IF	Citations
91	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. Journal of Immunology, 2009, 183, 2089-2096.	0.8	272
92	PPARÎ²/Î´ Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKCÎ±â€“Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1871-1873.	2.4	43
93	Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Experimental Cell Research, 2009, 315, 2974-2981.	2.6	17
94	Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96â€well microtiter plates. Journal of Thrombosis and Haemostasis, 2009, 7, 1226-1228.	3.8	4
95	Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. Journal of Thrombosis and Haemostasis, 2009, 7, 1897-1905.	3.8	23
96	Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. Journal of Thrombosis and Haemostasis, 2008, 6, 1933-1943.	3.8	61
97	COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet, The, 2008, 371, 270-273.	13.7	143
98	COXâ€1, and not COXâ€2 activity, regulates airway function: relevance to aspirinâ€sensitive asthma. FASEB Journal, 2008, 22, 4005-4010.	0.5	53
99	Interleukin-1Î², but not interleukin-6, enhances renal and systemic endothelin production in vivo. American Journal of Physiology - Renal Physiology, 2008, 295, F446-F453.	2.7	38
100	IDENTIFICATION AND CHARACTERIZATION OF A DYSFUNCTIONAL CARDIAC MYOCYTE PHENOTYPE: ROLE OF BACTERIA, TOLL-LIKE RECEPTORS, AND ENDOTHELIN. Shock, 2007, 28, 434-440.	2.1	6
101	Activation of PPARÎ²/Î´ Induces Endothelial Cell Proliferation and Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 63-69.	2.4	220
102	Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood, 2007, 109, 3741-3744.	1.4	75
103	Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2606-2611.	2.4	144
104	COX-2 in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 956-958.	2.4	52
105	The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 346, 919-925.	2.1	73
106	Increased thromboxane B2 levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Letters, 2006, 234, 193-198.	7.2	22
107	COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery, 2006, 5, 75-86.	46.4	235
108	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor Î² Receptors in Prostacyclin Sensing by Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 242-246.	2.9	79

#	Article	IF	Citations
109	The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression. Cancer Research, 2006, 66, 10120-10126.	0.9	157
110	Influence of plasma protein on the potencies of inhibitors of cyclooxygenaseâ€1 and â€2. FASEB Journal, 2006, 20, 542-544.	0.5	41
111	The Effect of NCX4016 [2-Acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl Ester] on the Consequences of Ischemia and Reperfusion in the Streptozotocin Diabetic Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1107-1114.	2.5	9
112	Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARÎ². FASEB Journal, 2006, 20, 326-328.	0.5	101
113	Stronger inhibition by nonsteroid antiâ€inflammatory drugs of cyclooxygenaseâ€1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB Journal, 2006, 20, 2468-2475.	0.5	71
114	NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. European Journal of Pharmacology, 2005, 508, 7-13.	3.5	6
115	Activation of peroxisome proliferator-activated receptor-Î³ by troglitazone (TGZ) inhibits human lung cell growth. Journal of Cellular Biochemistry, 2005, 96, 760-774.	2.6	61
116	Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4637-4642.	7.1	56
117	Cellular mechanisms of acetaminophen: role of cycloâ€oxygenase. FASEB Journal, 2005, 19, 1-15.	0.5	110
118	Discontinuation of Vioxx. Lancet, The, 2005, 365, 27-28.	13.7	4
119	The molecular and biological basis for COX-2 selectivity. , 2004, , 41-65.		0
120	Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I2: Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 642-647.	2.5	48
121	Expression and activation of the farnesoid X receptor in the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3668-3673.	7.1	203
122	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB Journal, 2004, 18, 790-804.	0.5	532
123	Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9108-9110.	7.1	17
124	PPARÎ³ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferatorâ€activated receptorâ€Î³ antagonist. FASEB Journal, 2003, 17, 1-15.	0.5	65
125	Role for Nuclear Factor-ÎºB and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells. Molecular Pharmacology, 2003, 64, 923-931.	2.3	58
126	HIF, stretching to get control of VEGF. Clinical Science, 2003, 105, 393-394.	4.3	9

#	Article	IF	Citations
127	Intimal Smooth Muscle Cells as a Target for Peroxisome Proliferator-Activated Receptor-Î³ Ligand Therapy. Circulation Research, 2002, 91, 210-217.	4.5	58
128	Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13371-13373.	7.1	252
129	Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension. Molecular Pharmacology, 2002, 62, 1147-1153.	2.3	27
130	Origins of Prostaglandin E2: Involvements of Cyclooxygenase (COX)-1 and COX-2 in Human and Rat Systems. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1001-1006.	2.5	105
131	MODULATION BY COLONY STIMULATING FACTORS OF HUMAN EPITHELIAL COLON CANCER CELL APOPTOSIS. Cytokine, 2002, 20, 163-167.	3.2	20
132	Cyclo-oxygenase-2 inhibitors and cardiovascular events. Lancet, The, 2002, 360, 1700-1701.	13.7	10
133	Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sciences, 2002, 71, 1893-1904.	4.3	24
134	Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. European Journal of Pharmacology, 2002, 440, 71-77.	3.5	2
135	Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. Clinical and Experimental Immunology, 2002, 127, 263-269.	2.6	45
136	Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. British Journal of Cancer, 2002, 86, 1316-1321.	6.4	10
137	Effects of nonâ€steroidal antiâ€inflammatory drugs on cycloâ€oxygenase and lipoxygenase activity in whole blood from aspirinâ€sensitive asthmatics vs healthy donors. British Journal of Pharmacology, 2002, 137, 1031-1038.	5.4	46
138	Endothelin content, expression, and receptor type in normal and diseased human gallbladder. Digestive Diseases and Sciences, 2002, 47, 1786-1792.	2.3	4
139	Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. European Journal of Medicinal Chemistry, 2001, 36, 517-530.	5.5	30
140	Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. British Journal of Pharmacology, 2001, 134, 1237-1244.	5.4	13
141	Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. European Journal of Pharmacology, 2001, 426, 95-103.	3.5	29
142	Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax, 2001, 56, 30-35.	5.6	163
143	Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 104-110.	2.9	77
144	Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 894-900.	2.5	12

#	Article	IF	Citations
145	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S407-S409.	1.9	20
146	Bisphenol A diglycidyl ether (BADGE) is a PPARÎ³ agonist in an ECV304 cell line. British Journal of Pharmacology, 2000, 131, 651-654.	5.4	60
147	Effects of nitric oxide-modulating amino acids on coronary vessels: relevance to sepsis. European Journal of Pharmacology, 2000, 389, 209-215.	3.5	16
148	Cyclic AMP Regulates Cytokine Stimulation of Endothelin-1 Release in Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S404-S406.	1.9	6
149	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S407-S409.	1.9	3
150	The Prostacyclin-Mimetic Cicaprost Inhibits Endogenous Endothelin-1 Release From Human Pulmonary Artery Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, S410-S413.	1.9	30
151	Nomenclature for COX-2 Inhibitors. Lancet, The, 2000, 356, 1373-1374.	13.7	46
152	Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. Free Radical Research, 2000, 32, 223-234.	3.3	24
153	Synergy between cycloâ€oxygenaseâ€2 induction and arachidonic acid supplyin vivo: consequences for nonsteroidal antiinflammatory drug efficacy. FASEB Journal, 1999, 13, 245-251.	0.5	44
154	Selective COXâ€2 inhibitors and human inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 1999, 13, 1115-1117.	3.7	67
155	RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 247-252.	1.9	62
156	Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. British Journal of Pharmacology, 1999, 126, 1824-1830.	5.4	77
157	A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. British Journal of Pharmacology, 1999, 127, 1589-1596.	5.4	74
158	Cycloâ€oxygenaseâ€2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. British Journal of Pharmacology, 1999, 128, 1121-1132.	5.4	234
159	Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7563-7568.	7.1	1,436
160	Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-ÎºB activation. Life Sciences, 1999, 64, 1231-1242.	4.3	31
161	Endothelin Receptors and Ligands. , 1999, , 21-48.		0
162	Nitric oxide and endothelin-1 in circulatory shock involving cytokines. , 1999, , 151-171.		0

#	Article	IF	Citations
163	Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. Journal of Pharmacology and Experimental Therapeutics, 1999, 288, 1101-6.	2.5	23
164	Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Molecular Pharmacology, 1999, 55, 902-9.	2.3	93
165	Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo : investigations using the selective inhibitors, 1400W and celecoxib. British Journal of Pharmacology, 1998, 125, 335-340.	5.4	52
166	Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 121-125.	3.0	7
167	Regulation of Cyclo-oxygenase Gene Expression in Rat Smooth Muscle Cells by Catalase. Biochemical Pharmacology, 1998, 55, 1621-1631.	4.4	39
168	NOS inhibitors in colitis: a suitable case for treatment?. Gut, 1998, 42, 152-153.	12.1	6
169	Cytokine and Lipopolysaccharide Stimulation of Endothelin-1 Release from Human Internal Mammary Artery and Saphenous Vein Smooth-Muscle Cells. Journal of Cardiovascular Pharmacology, 1998, 31, S348-S350.	1.9	38
170	Cytokine Regulation of Endothelin Action. , 1998, , 89-100.		0
171	The Development of Specific Endothelin-Receptor Antagonists. , 1998, , 189-222.		0
172	Shock news for the gut. Gut, 1998, 42, 606-606.	12.1	2
173	Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. European Journal of Pharmacology, 1997, 324, 219-222.	3.5	19
174	Regulation of blood pressure by l-arginine-nitric oxide pathway within the superior colliculus of rats. European Journal of Pharmacology, 1997, 328, 65-67.	3.5	3
175	Activation of ETa receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. Life Sciences, 1997, 60, PL271-PL276.	4.3	3
176	Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. British Journal of Pharmacology, 1997, 121, 125-133.	5.4	87
177	A Single Competitive Reverse Transcriptase-Polymerase Chain Reaction Assay to Measure Inducible Nitric Oxide Synthase Gene Expression in Both Human and Rat. Analytical Biochemistry, 1997, 247, 455-458.	2.4	2
178	Endothelinâ€1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. British Journal of Pharmacology, 1996, 118, 21-26.	5.4	10
179	Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats. European Journal of Pharmacology, 1996, 316, 245-247.	3.5	5
180	What turns on the endothelins?. Inflammation Research, 1996, 45, 51-53.	4.0	33

#	Article	IF	Citations
181	Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. International Angiology, 1996, 15, 93-9.	0.9	12
182	Endothelin versatility. Nature, 1995, 375, 539-540.	27.8	25
183	N^G-Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts. Endothelium: Journal of Endothelial Cell Research, 1995, 3, 121-129.	1.7	1
184	Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2691-2695.	7.1	82
185	Roles of endothelin receptors in the regional and systemic vascular responses to ETâ€1 in the anaesthetized ganglionâ€blocked rat: use of selective antagonists. British Journal of Pharmacology, 1995, 116, 2482-2486.	5.4	32
186	The contribution of tumour necrosis factorâ€Î± and endothelinâ€1 to the increase of coronary resistance in hearts from rats treated with endotoxin. British Journal of Pharmacology, 1995, 116, 3309-3315.	5.4	52
187	Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. British Journal of Pharmacology, 1995, 116, 2787-2789.	5.4	7
188	Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. British Journal of Pharmacology, 1995, 114, 867-871.	5.4	10
189	Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670. British Journal of Pharmacology, 1995, 114, 1327-1328.	5.4	4
190	Coâ€induction of nitric oxide synthase and cycloâ€oxygenase: interactions between nitric oxide and prostanoids. British Journal of Pharmacology, 1995, 114, 1335-1342.	5.4	318
191	Contractile activity of endothelin precursors in the isolated gallbladder of the guineaâ€pig: presence of an endothelinâ€converting enzyme. British Journal of Pharmacology, 1995, 114, 1383-1390.	5.4	4
192	Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. British Journal of Pharmacology, 1995, 114, 1673-1679.	5.4	44
193	Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guineaâ€pig. British Journal of Pharmacology, 1995, 115, 1319-1325.	5.4	30
194	Inhibition of ETB Receptors Limits the Efficacy of Nonselective Endothelin Antagonists In Vivo. Journal of Cardiovascular Pharmacology, 1995, 26, S177-179.	1.9	11
195	Endothelin-1 Mediates Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines. Journal of Cardiovascular Pharmacology, 1995, 26, S419-421.	1.9	14
196	Endothelins: Recent Progress. , 1995, , 313-318.		0
197	Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. Journal of Pharmacology and Experimental Therapeutics, 1995, 275, 120-6.	2.5	13
198	Endothelin-1 Mediates the Increase in Ex Vivo Coronary Vascular Resistance Induced by Hemorrhagic Shock in the Anesthetized Rat. Journal of Cardiovascular Pharmacology, 1995, 26, S422-424.	1.9	0

#	Article	IF	Citations
199	Irish society for gastroenterology. Irish Journal of Medical Science, 1994, 163, 37-47.	1.5	0
200	Endothelin Receptor Antagonists. Cardiovascular Drug Reviews, 1994, 12, 105-122.	4.1	34
201	Synthesis and biological activity of the novel nitric oxide synthase inhibitor NÏ‰â€²-hydroxy-NÏ‰-methyl-L-arginine. Journal of the Chemical Society Perkin Transactions 1, 1994, , 769-771.	0.9	14
202	Endothelin-1 Release from Endothelial Cells in Culture Is Elevated Both Acutely and Chronically by Short Periods of Mechanical Stretch. Biochemical and Biophysical Research Communications, 1994, 200, 395-400.	2.1	147
203	Endothelin receptor antagonists: Actions and rationale for their development. Biochemical Pharmacology, 1994, 48, 625-635.	4.4	42
204	Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. European Journal of Pharmacology, 1994, 252, 341-345.	3.5	11
205	Reversal of established responses to endothelinâ€1 in vivo and in vitro by the endothelin receptor antagonists, BQâ€123 and PD 145065. British Journal of Pharmacology, 1994, 112, 207-213.	5.4	59
206	The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. British Journal of Pharmacology, 1994, 112, 289-291.	5.4	17
207	Characterization of endothelin (ET) receptors in the isolated gall bladder of the guineaâ€pig: evidence for an additional ET receptor subtype. British Journal of Pharmacology, 1994, 112, 1244-1250.	5.4	27
208	5â€HT₃ receptors do not mediate vagallyâ€induced relaxation or contraction of the isolated stomach of the guineaâ€pig. British Journal of Pharmacology, 1994, 111, 346-350.	5.4	5
209	Evidence from receptor antagonists of an important role for ET_B receptorâ€mediated vasoconstrictor effects of endothelinâ€1 in the rat kidney. British Journal of Pharmacology, 1994, 111, 515-520.	5.4	60
210	Characterization of ET_B receptors mediating contractions induced by endothelinâ€1 or IRL 1620 in guineaâ€pig isolated airways: effects of BQâ€123, FR139317 or PD 145065. British Journal of Pharmacology, 1994, 111, 1009-1016.	5.4	49
211	Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach. British Journal of Pharmacology, 1994, 113, 1197-1202.	5.4	47
212	Effects of Cyclic GMP on Smooth Muscle Relaxation. Advances in Pharmacology, 1994, 26, 171-194.	2.0	106
213	Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. Polish Journal of Pharmacology, 1994, 46, 587-92.	0.3	5
214	ET touches down in Houston. Nature, 1993, 362, 497-498.	27.8	6
215	Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. European Journal of Pharmacology, 1993, 250, 447-453.	3.5	37
216	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. British Journal of Pharmacology, 1993, 108, 776-779.	5.4	123

#	Article	IF	Citations
217	Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. British Journal of Pharmacology, 1993, 109, 265-270.	5.4	126
218	Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. British Journal of Pharmacology, 1993, 110, 687-692.	5.4	44
219	Use of the endothelin antagonists BQâ€123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. British Journal of Pharmacology, 1993, 110, 777-782.	5.4	165
220	Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guineaâ€pig ileum. British Journal of Pharmacology, 1993, 110, 783-789.	5.4	35
221	The Metabolism of Endothelin-1 and Big Endothelin-1 by the Isolated Perfused Kidney of the Rabbit. Journal of Cardiovascular Pharmacology, 1993, 22, S65-S68.	1.9	2
222	Comparative Studies with the Endothelin Receptor Antagonists BQ-123 and PD 142893 Indicate At Least Three Endothelin Receptors. Journal of Cardiovascular Pharmacology, 1993, 22, S117-S120.	1.9	50
223	Vasoconstriction in the Rat Kidney Induced by Endothelin-1 Is Blocked by PD 145065. Journal of Cardiovascular Pharmacology, 1993, 22, S103-S106.	1.9	19
224	Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. European Heart Journal, 1993, 14 Suppl I, 42-7.	2.2	3
225	Characterization of Serine Protease-Derived Metabolites of Big Endothelin in the Cytosolic Fraction from Human Polymorphonuclear Leukocytes. Journal of Cardiovascular Pharmacology, 1992, 20, S22-S24.	1.9	11
226	Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science, 1992, 255, 721-723.	12.6	419
227	Detection by Bioassay and Specific Enzyme-Linked Immunosorbent Assay of Phosphoramidon-Inhibitable Endothelin-Converting Activity in Brain and Endothelium. Journal of Cardiovascular Pharmacology, 1992, 20, S19-S21.	1.9	7
228	Different patterns of release of endotheliumâ€derived relaxing factor and prostacyclin. British Journal of Pharmacology, 1992, 105, 485-489.	5.4	36
229	Human brain contains a metalloprotease that converts big endothelinâ€1 to endothelinâ€1 and is inhibited by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 505-506.	5.4	15
230	Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. British Journal of Pharmacology, 1992, 106, 948-952.	5.4	27
231	Nitric oxide synthase in ferret brain: localization and characterization. British Journal of Pharmacology, 1992, 107, 849-852.	5.4	9
232	Double-edged role of endogenous nitric oxide. Lancet, The, 1992, 339, 986.	13.7	24
233	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. Methods, 1992, 1, 117-123.	0.5	1
234	Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. American Journal of Physiology - Heart and Circulatory Physiology, 1992, 262, H1600-H1605.	3.2	14

#	Article	IF	Citations
235	Response : Nitric Oxide and Arginine-Evoked Insulin Secretion. Science, 1992, 258, 1376-1378.	12.6	0
236	Response : Nitric Oxide and Arginine-Evoked Insulin Secretion. Science, 1992, 258, 1376-1378.	12.6	3
237	Characterization of endothelin-converting enzyme from endothelial cells and rat brain: detection of the formation of biologically active endothelin-1 by rapid bioassay. Molecular Pharmacology, 1992, 41, 399-403.	2.3	13
238	Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Molecular Pharmacology, 1992, 41, 615-24.	2.3	209
239	Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages. Molecular Pharmacology, 1992, 41, 1163-8.	2.3	39
240	Alkaline buffers release EDRF from bovine cultured aortic endothelial cells. British Journal of Pharmacology, 1991, 103, 1295-1302.	5.4	24
241	Endothelial cells have a particulate enzyme system responsible for EDRF formation: Measurement by vascular relaxation. Biochemical and Biophysical Research Communications, 1991, 176, 1417-1423.	2.1	45
242	Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. European Journal of Pharmacology, 1991, 204, 329-334.	3.5	56
243	Isoforms of nitric oxide synthase Characterization and purification from different cell types. Biochemical Pharmacology, 1991, 42, 1849-1857.	4.4	813
244	A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. American Journal of Physiology - Heart and Circulatory Physiology, 1991, 261, H598-H603.	3.2	47
245	Human Big Endothelin Releases Prostacyclin in vivo and in vitro Through a Phosphoramidon-Sensitive Conversion to Endothelin-1. Journal of Cardiovascular Pharmacology, 1991, 17, S251-255.	1.9	24
246	Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10480-10484.	7.1	897
247	Endothelin-1 Stimulates Cyclic GMP Formation in Porcine Kidney Epithelial Cells via Activation of the L-Arginine-Dependent Soluble Guanylate Cyclase Pathway. Journal of Cardiovascular Pharmacology, 1991, 17, S246-250.	1.9	6
248	Endothelin increases cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance. Journal of Pharmacology and Experimental Therapeutics, 1991, 259, 1102-8.	2.5	27
249	Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. Biochemical Pharmacology, 1990, 39, R21-R22.	4.4	53
250	Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. Biochemical and Biophysical Research Communications, 1990, 172, 745-750.	2.1	9
251	Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. British Journal of Pharmacology, 1990, 99, 427-433.	5.4	76
252	Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. Journal of Cardiovascular Pharmacology, 1989, 13, S85-88.	1.9	276

#	Article	IF	Citations
253	Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. European Journal of Pharmacology, 1989, 159, 325-326.	3.5	257
254	Comparison of the survival of endotheliumâ€derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat. British Journal of Pharmacology, 1989, 97, 777-782.	5.4	8
255	Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9797-9800.	7.1	1,293
256	Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2334-2338.	7.1	250